INCB 50465-304: A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
Principal investigator: Minna Lehto HUS Helsinki University Hospital, Comprehensive Cancer Center